Clinical Trial Update: Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the treatment of hereditary angioedema prodrome with recombinant C1-esterase inhibitor (Ruconest) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Ruconest (conestat alfa)

Snippet

Sponsor: Bernstein Clinical Research Center | Conditions: Hereditary Angioedema | Phase 4 | Status: COMPLETED